The experience of real practice antiviral therapy of chronic hepatitis D in the Republic of Crimea
Journal: Infekcionnye bolezni
Year: 2023

Objective. The analysis of the results of antiviral therapy of chronic hepatitis D (HDV) in real practice using bulevirtide, an inhibitor of the entry of hepatitis B and D viruses (HDV) into the hepatocyte. Patients and methods. Intermediate treatment results were studied in 6 patients with HDV, including 3 patients with compensated cirrhosis who received bulevirtide in combination with pegylated interferon-α for 48 weeks, as well as in 3 patients who continued treatment (in combination therapy